Skip to main content
Clinical Trials/NCT05455281
NCT05455281
Completed
N/A

A Pilot, Observational, Prospective Study to Evaluate the Performance of CHLOE Algorithm on the Prediction of Blastocyst Formation in Women Undergoing In-vitro Fertilization

Fairtility3 sites in 2 countries55 target enrollmentJuly 27, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fertility Disorders
Sponsor
Fairtility
Enrollment
55
Locations
3
Primary Endpoint
The association between the adjunct prediction using CHLOE of blastocyst outcome and the actual blastocyst outcome for a subset of good/fair embryos
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is an observational, prospective, single-arm, multi-center, clinical study to evaluate the performance of CHLOE, an Artificial Intelligence (AI)-based software application, as adjunct information to support identifying embryos on Day 3 that are most likely to form blastocysts.

Detailed Description

The study is an observational, prospective, single-arm, multi-center, clinical study in order to evaluate the performance of CHLOE, an Artificial Intelligence (AI)-based software application, as adjunct information to support identifying embryos on Day 3 that are most likely to form blastocysts on Day 5.

Registry
clinicaltrials.gov
Start Date
July 27, 2022
End Date
July 27, 2023
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Fairtility
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women undergoing fresh IVF treatment using their own eggs
  • At least 18 years of age
  • Total antral follicle count (AFC) of at least 12 as measured by ultrasound prior to stimulation (in cases where AFC is performed)
  • Basal day 3 follicle-stimulating hormone levels (FSH) \< 10 IU
  • At least 8 normally fertilized eggs at pronuclear (2PN) stage
  • Fertilization using only ejaculated sperm (fresh or frozen) - no surgically removed sperm
  • At least 2 cells embryo
  • At least part of the embryos were cultured until Day 5 (i.e., 114-116 hours)
  • IVF treatment cycles were performed during 2020-2021

Exclusion Criteria

  • Use of re-inseminated eggs
  • Embryos that underwent day 3 biopsy for preimplantation genetic testing (PGT)
  • Gestational carriers
  • Concurrent participation in another clinical study
  • Previous enrollment in this clinical study (i.e., previous cycles of the same women)
  • History of cancer
  • Embryos that underwent biopsy at cleavage stage

Outcomes

Primary Outcomes

The association between the adjunct prediction using CHLOE of blastocyst outcome and the actual blastocyst outcome for a subset of good/fair embryos

Time Frame: 3 days

The prediction of blastocyst outcome using CHLOE algorithm, and the actual blastocyst outcome for a subset of good/fair embryos will be measured using odds ratio.

Secondary Outcomes

  • The association between the adjunct prediction using CHLOE of blastocyst outcome and the actual blastocyst outcome for all embryos(3 days)
  • Blastocyst formation using traditional human morphology only for all embryos(3 days)
  • Blastocyst formation based on the CHLOE algorithm prediction for a subset of good/fair embryos(3 days)

Study Sites (3)

Loading locations...

Similar Trials